CN114728003B - 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合 - Google Patents

治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合 Download PDF

Info

Publication number
CN114728003B
CN114728003B CN202080076132.6A CN202080076132A CN114728003B CN 114728003 B CN114728003 B CN 114728003B CN 202080076132 A CN202080076132 A CN 202080076132A CN 114728003 B CN114728003 B CN 114728003B
Authority
CN
China
Prior art keywords
capecitabine
administered
pharmaceutically acceptable
acartinib
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080076132.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN114728003A (zh
Inventor
H·德里
B·威利斯
A·布勒赫尔
J·梅特塔尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN114728003A publication Critical patent/CN114728003A/zh
Application granted granted Critical
Publication of CN114728003B publication Critical patent/CN114728003B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080076132.6A 2019-11-04 2020-10-30 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合 Active CN114728003B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930208P 2019-11-04 2019-11-04
US62/930208 2019-11-04
PCT/EP2020/080493 WO2021089419A1 (en) 2019-11-04 2020-10-30 Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies

Publications (2)

Publication Number Publication Date
CN114728003A CN114728003A (zh) 2022-07-08
CN114728003B true CN114728003B (zh) 2025-01-28

Family

ID=73043259

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080076132.6A Active CN114728003B (zh) 2019-11-04 2020-10-30 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合

Country Status (14)

Country Link
US (1) US12691113B2 (cg-RX-API-DMAC7.html)
EP (1) EP4054582B1 (cg-RX-API-DMAC7.html)
JP (1) JP7575454B2 (cg-RX-API-DMAC7.html)
KR (1) KR102984130B1 (cg-RX-API-DMAC7.html)
CN (1) CN114728003B (cg-RX-API-DMAC7.html)
AU (1) AU2020381240C1 (cg-RX-API-DMAC7.html)
CA (1) CA3158321A1 (cg-RX-API-DMAC7.html)
DK (1) DK4054582T3 (cg-RX-API-DMAC7.html)
ES (1) ES3055126T3 (cg-RX-API-DMAC7.html)
FI (1) FI4054582T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022005250A (cg-RX-API-DMAC7.html)
PL (1) PL4054582T3 (cg-RX-API-DMAC7.html)
PT (1) PT4054582T (cg-RX-API-DMAC7.html)
WO (1) WO2021089419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230286A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2024104561A1 (en) * 2022-11-15 2024-05-23 Astrazeneca Ab Therapeutic combinations of capivasertib and venetoclax

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
AU2014360537B2 (en) * 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
EP3076974A1 (en) * 2013-12-05 2016-10-12 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
JP6785804B2 (ja) * 2015-06-23 2020-11-18 ギリアド サイエンシズ, インコーポレイテッド B細胞悪性腫瘍を治療するための組合せ療法
US20170071962A1 (en) 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
BR112017002594A2 (pt) * 2015-12-17 2017-12-19 Gilead Sciences Inc compostos inibidores de cinase de ligação de tank
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
AU2018335617B2 (en) * 2017-09-25 2021-12-09 Astrazeneca Ab Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
KR20250119664A (ko) 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Acalabrutinib (ACP-196): a selective secondgeneration BTK inhibitor;Jingjing Wu;Journal of Hematology & Oncology;第9卷(第1期);1-4 *
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL;Tabea Erdmann;Blood;第130卷(第3期);310-322 *

Also Published As

Publication number Publication date
JP7575454B2 (ja) 2024-10-29
JP2023501317A (ja) 2023-01-18
PL4054582T3 (pl) 2026-02-16
EP4054582B1 (en) 2025-09-03
FI4054582T3 (fi) 2025-12-04
CA3158321A1 (en) 2021-05-14
KR20220098175A (ko) 2022-07-11
EP4054582A1 (en) 2022-09-14
DK4054582T3 (da) 2025-12-01
PT4054582T (pt) 2025-12-10
AU2020381240C1 (en) 2024-02-15
WO2021089419A1 (en) 2021-05-14
AU2020381240A1 (en) 2022-06-23
US20220401442A1 (en) 2022-12-22
KR102984130B1 (ko) 2026-07-01
CN114728003A (zh) 2022-07-08
US12691113B2 (en) 2026-07-28
AU2020381240B2 (en) 2023-09-07
MX2022005250A (es) 2022-06-08
ES3055126T3 (en) 2026-02-10

Similar Documents

Publication Publication Date Title
JP2023058582A (ja) 神経芽細胞腫の治療における使用のためのオーロラaキナーゼ阻害剤
US10463668B2 (en) Methods of treating and preventing graft versus host disease
RU2695228C2 (ru) Прерывистое введение ингибитора mdm2
US20180078558A1 (en) Methods of treating and preventing alloantibody driven chronic graft versus host disease
KR20240074779A (ko) 약학적 조성물 및 이의 용도
TW201330845A (zh) 胰臟癌及/或膽道癌治療劑
US20120308562A1 (en) Methods of treating mesothelioma with a pi3k inhibitor compound
CN113194952A (zh) Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
JP7703124B1 (ja) Serd投薬レジメンの組み合わせを使用してがんを治療する方法
CN113453671A (zh) 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法
CN116159062A (zh) 药物组合物及其用途
AU2020381240B2 (en) Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
EP3880207B1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
HK40069821A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
HK40069821B (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
TWI671072B (zh) 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合
EA045670B1 (ru) Терапевтические комбинации акалабрутиниба и капивасертиба для лечения в-клеточных злокачественных образований
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
EP4452275B1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
EP4729061A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
CN120322232A (zh) 喹诺林化合物治疗小细胞肺癌的用途
WO2026076264A1 (en) Treatment of lymphomas using an ezh2 inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40069821

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant